Close Menu

NEW YORK (360Dx) – Luminex said this week that it has reached an agreement whereby Laboratory Corporation of America is extending its commitment to the Luminex Cystic Fibrosis product line through Dec. 31, 2019. LabCorp would, therefore, maintain at least its current volume of CF testing with Luminex through 2019, Luminex said.

In a separate announcement, Luminex said that its board of directors declared a cash dividend for the third quarter of 2017 of $.06 per share of common stock payable on Oct. 13 to stockholders of record at the close of business on Sept. 22.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.